Cadrenal Therapeutics, Inc. - Common Stock

Share · US1276361086 · CVKD (XNAS)

Overview

AI-Powered Analysis

Fundamental Analysis

Find out what the numbers really say — before the market does

Analyze now

News Sentiment

Are today's headlines a buy signal or a red flag?

Analyze now

Buy / Hold / Sell

Should you Buy, Hold, or Sell? Get the AI verdict now.

Analyze now

Risk Assessment

Uncover hidden risks before they hit your portfolio.

Analyze now

Fair Value

Is this stock cheap, fairly priced, or overvalued?

Analyze now

Latest AI Analyses of Cadrenal Therapeutics, Inc. - Common Stock

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

No Price

28.04.2026 20:00

Current Prices from Cadrenal Therapeutics, Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	CVKD	USD	28.04.2026 20:00	5,33 USD	-0,37 USD -6,49 %
IEX	CVKD	USD	28.04.2026 14:46	5,60 USD	-0,10 USD -1,75 %

Share Float & Liquidity

Free Float 77,63 %

Shares Float 1,95 M

Shares Outstanding 2,51 M

Company Profile for Cadrenal Therapeutics, Inc. - Common Stock Share

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.